{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:35:06Z","timestamp":1790411706872,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,7]],"date-time":"2016-08-07T00:00:00Z","timestamp":1470528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.atherosclerosis.2016.07.925","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T12:29:21Z","timestamp":1469968161000},"page":"182-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Dyslipidaemia in the Middle East: Current status and a call for action"],"prefix":"10.1016","volume":"252","author":[{"given":"Khalid","family":"Al Rasadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Almahmeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid F.","family":"AlHabib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Abifadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan Ali","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saud","family":"AlSifri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Jambart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Zubaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhier","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al-Waili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Barter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9991","key":"10.1016\/j.atherosclerosis.2016.07.925_bib1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0140-6736(15)60265-3","article-title":"The World Heart Federation's vision for worldwide cardiovascular disease prevention","volume":"386","author":"Yusuf","year":"2015","journal-title":"Lancet"},{"issue":"3 suppl","key":"10.1016\/j.atherosclerosis.2016.07.925_bib2","doi-asserted-by":"crossref","first-page":"83S","DOI":"10.1177\/1010539510373034","article-title":"Cardiovascular disease in the Asia Middle East region: global trends and local implications","volume":"22","author":"Ramahi","year":"2010","journal-title":"Asia-Pacific J. Public Health"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.07.925_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2143\/AC.64.4.2041607","article-title":"Management and outcomes of middle eastern patients admitted with acute coronary syndromes in the Gulf registry of acute coronary events (Gulf RACE)","volume":"64","author":"Zubaid","year":"2009","journal-title":"Acta Cardiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.07.925_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/2047487312465525","article-title":"Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study","volume":"21","author":"Gehani","year":"2014","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"7550","key":"10.1016\/j.atherosclerosis.2016.07.925_bib5","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/bmj.38793.468449.AE","article-title":"Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials","volume":"332","author":"Costa","year":"2006","journal-title":"BMJ."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.07.925_bib6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.07.925_bib7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MOL.0b013e32800ff750","article-title":"Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials","volume":"17","author":"Brown","year":"2006","journal-title":"Curr. Opin. Lipidol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.07.925_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.repc.2014.08.020","article-title":"Prevalence of dyslipidemia in adolescents: Comparison between definitions","volume":"34","author":"Tomeleri","year":"2015","journal-title":"Rev. Port. Cardiol. English Ed."},{"key":"10.1016\/j.atherosclerosis.2016.07.925_bib9","first-page":"13","article-title":"Secular trends in serum lipid levels of a Middle Eastern adult population; 10 years follow up in Tehran lipid and glucose study","volume":"23","author":"Kheirandish","year":"2014","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2016.07.925_bib10","first-page":"2015","article-title":"Prevalence of cardiovascular disease and associated risk factors among adult population in the Gulf region: a systematic review","author":"Aljefree","year":"2015","journal-title":"Adv. Public Health"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.07.925_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1258\/shorts.2011.011019","article-title":"Prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: systematic review","volume":"2","author":"Alhyas","year":"2011","journal-title":"JRSM Short. Rep."},{"key":"10.1016\/j.atherosclerosis.2016.07.925_bib12","series-title":"Cardiovascular Risk Factor Burden in Africa and the Middle East: The Africa Middle East Cardiovascular Epidemiological (ACE) Study","author":"Alsheikh-Ali","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2016.07.925_bib13","series-title":"Ethnic Difference in Lipid Profiles","author":"Zhang","year":"2012"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2016.07.925_bib14","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","author":"Panel","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.07.925_bib15","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1185\/030079908X280527","article-title":"Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia","volume":"24","author":"Bays","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.07.925_bib16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/CIRCULATIONAHA.105.552737","article-title":"Dyslipidemia prevalence, treatment, and control in the multi-ethnic study of atherosclerosis (MESA) gender, ethnicity, and coronary artery calcium","volume":"113","author":"Goff","year":"2006","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.07.925_bib17","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.17269\/cjph.104.3783","article-title":"Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health measures survey","volume":"104","author":"Joffres","year":"2013","journal-title":"Can. J. Public Health"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.07.925_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1475-2840-7-31","article-title":"Dyslipidemia in primary care\u2013prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)","volume":"7","author":"Steinhagen-Thiessen","year":"2008","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.07.925_bib19","first-page":"420","article-title":"I\u00a0cardiovascular prevention guideline of the Brazilian Society of Cardiology-executive summary","volume":"102","author":"Sim\u00e3o","year":"2014","journal-title":"Arq. Bras. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.07.925_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/HJR.0b013e328322ca1b","article-title":"Prevalence of cardiovascular risk factors in the Middle East: a systematic review","volume":"16","author":"Motlagh","year":"2009","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.07.925_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/clc.20873","article-title":"Prevalence and impact of cardiovascular risk factors among patients presenting with acute coronary syndrome in the middle East","volume":"34","author":"El-Menyar","year":"2011","journal-title":"Clin. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.07.925_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5144\/0256-4947.2012.9","article-title":"Baseline characteristics, management practices, and long-term outcomes of middle eastern patients in the second Gulf registry of acute coronary events (Gulf RACE-2)","volume":"32","author":"AlHabib","year":"2012","journal-title":"Ann. Saudi Med."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2016.07.925_bib23","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"The task force for the management of dyslipidaemias of the European society of Cardiology (ESC) and the European atherosclerosis society (EAS). ESC\/EAS guidelines for the management of dyslipidaemias","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.07.925_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report","volume":"8","author":"Grundy","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.07.925_bib25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1\u2013executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.07.925_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arteriosclerosis, thrombosis, Vasc. Biol."},{"issue":"4145","key":"10.1016\/j.atherosclerosis.2016.07.925_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1126\/science.185.4145.61","article-title":"Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man","volume":"185","author":"Brown","year":"1974","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2016.07.925_bib28","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.84.19.6919","article-title":"Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding","volume":"84","author":"Innerarity","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.07.925_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"5520","key":"10.1016\/j.atherosclerosis.2016.07.925_bib30","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1060458","article-title":"Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein","volume":"292","author":"Garcia","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.07.925_bib31","first-page":"139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the national lipid association expert panel on familial hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J.\u00a0Manag. Care Pharm."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.07.925_bib32","doi-asserted-by":"crossref","first-page":"E682","DOI":"10.1002\/humu.21002","article-title":"The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum. Mutat."},{"issue":"1\u20132","key":"10.1016\/j.atherosclerosis.2016.07.925_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000175431","article-title":"Experiences with the homozygous cases of familial hypercholesterolemia","volume":"15","author":"Khachadurian","year":"1973","journal-title":"Ann. Nutr. Metab."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.07.925_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jacl.2014.11.008","article-title":"Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry","volume":"9","author":"Bamimore","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"45","key":"10.1016\/j.atherosclerosis.2016.07.925_bib35","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. heart J."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2016.07.925_bib36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/jmg.32.8.623","article-title":"Consanguinity among the Saudi Arabian population","volume":"32","author":"El-Hazmi","year":"1995","journal-title":"J.\u00a0Med. Genet."},{"issue":"9860","key":"10.1016\/j.atherosclerosis.2016.07.925_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2016.07.925_bib38","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2016.07.925_bib39","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.07.925_bib40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/1570161113666150827125040","article-title":"Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a Middle East advisory panel","volume":"13","author":"Al-Ashwal","year":"2015","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2016.07.925_bib41","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0003319713512414","article-title":"Centralized Pan-Middle East survey on the undertreatment of hypercholesterolemia results from the CEPHEUS study in Arabian Gulf countries","volume":"65","author":"Arafah","year":"2014","journal-title":"Angiology"},{"key":"10.1016\/j.atherosclerosis.2016.07.925_bib42","series-title":"Results of the Dyslipidemia International Study (DYSIS)-middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalities in the Setting of Chronic Statin Treatment","author":"Al Sifri","year":"2014"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.07.925_bib43","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.07.925_bib44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","article-title":"Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada","volume":"19","author":"Gitt","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.07.925_bib45","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/HJR.0b013e3283383f30","article-title":"EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries","volume":"17","author":"Kotseva","year":"2010","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.07.925_bib46","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.108.838466","article-title":"Lipid treatment assessment project 2 a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol Goals","volume":"120","author":"Waters","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.07.925_bib47","series-title":"ACC Expert Consensus Decision Pathway on the Role of Non-statin Therapies for LDL-cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk","author":"AACC","year":"2016"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.07.925_bib48","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1185\/03007995.2014.965774","article-title":"Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf","volume":"30","author":"Al-Rasadi","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2016.07.925_bib49","doi-asserted-by":"crossref","first-page":"i721","DOI":"10.1136\/bmj.i721","article-title":"Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study","volume":"352","author":"Jousilahti","year":"2016","journal-title":"bmj"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.07.925_bib50","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non\u2013HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.07.925_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"Banach","year":"2015","journal-title":"Arch. Med. Sci."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016312266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016312266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:55:29Z","timestamp":1761191729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016312266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":51,"alternative-id":["S0021915016312266"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.07.925","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dyslipidaemia in the Middle East: Current status and a call for action","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.07.925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}